Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 combined with PD-1 antibody in advanced or metastatic solid tumors including non-small cell lung cancer and nasopharyngeal carcinoma
CTR20242274Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC) (4 arms), sponsored by Biokin Pharmaceutical. Primary endpoints: Objective response rate and Recommended phase II dose and combination regimen. Started Jul 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20242274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242274.